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Abstract
Rationale—Direct conversion or reprogramming of human postnatal cells into endothelial cells 
(ECs), bypassing stem or progenitor cell status, is crucial for regenerative medicine, cell therapy, 
and pathophysiological investigation but has remained largely unexplored.
Objective—We sought to directly reprogram human postnatal dermal fibroblasts (HDFs) to ECs 
with vasculogenic and endothelial transcription factors (TFs) and determine their vascularizing 
and therapeutic potential.
Methods and Results—We utilized various combinations of seven EC TFs to transduce HDFs 
and found that ER71/ETV2 alone best induced endothelial features. KDR+ cells sorted at day 7 
from ER71/ETV2-transduced HDFs showed less mature but enriched endothelial characteristics 
and thus were referred to as early reprogrammed ECs (rECs), and did not undergo maturation by 
further culture. After a period of several weeks’ transgene-free culture followed by transient re-
induction of ER71/ETV2, early rECs matured during three months of culture and showed reduced 
ETV2 expression, reaching a mature phenotype similar to postnatal human ECs. These were 
termed late rECs. While early rECs exhibited an immature phenotype, their implantation into 
ischemic hindlimbs induced enhanced recovery from ischemia. These two rECs showed clear 
capacity for contributing to new vessel formation through direct vascular incorporation in vivo. 
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Paracrine or pro-angiogenic effects of implanted early rECs played a significant role in repairing 
hindlimb ischemia.
Conclusions—This study for the first time demonstrates that ER71/ETV2 alone can directly 
reprogram human postnatal cells to functional, mature ECs after an intervening transgene free 
period. These rECs could be valuable for cell therapy, personalized disease investigation, and 
exploration of the reprogramming process.
Keywords
Direct reprogramming; ER71/ETV2; endothelial cells; ets transcription factors; 
transdifferentiation; angiogenesis
INTRODUCTION
Endothelial cells (ECs) are a key element of vasculature and are indispensable for repairing 
injured or ischemic tissues. Over the years, many approaches have been developed to 
generate ECs for use in cell therapy. Despite early enthusiasm, adult stem or progenitor cells 
were found to have minimal endothelial transdifferentiation potential1–3. Embryonic stem 
cells (ESCs) and induced pluripotent stem cells (iPSCs) emerged as promising alternatives; 
however, problems such as tumorigenic potential or inefficient cell production have limited 
their clinical application4–6. Recently, a new approach has been developed for generating 
target cells through direct lineage conversion or reprogramming with cell-type specific 
transcription factors (TFs)7–12. This approach has many potential advantages such as 
procedural simplicity and avoidance of uncontrolled differentiation and tumorigenicity 
compared to ESCs and iPSCs.
In an attempt to generate ECs directly from somatic cells, one recent study demonstrated 
direct conversion of lineage committed cells into ECs via lentiviral overexpression of a 
combination of ETV2 (also known as ER71), ERG, and FLI1 with inhibition of TGFβ 
signaling7. This method, however, utilized amniotic fluid-derived c-KIT-negative cells as 
source cells, and reportedly did not work for postnatal cells. It is also unclear whether the 
source cells were fully differentiated, since their origin was amniotic tissues13 and potential 
contamination with stem or progenitor cells cannot be entirely excluded. Due to cell 
heterogeneity, clonal variability of reprogrammed cells was noted as well. Practically, this 
approach needs invasive amniocentesis and cannot be applied for autologous cell therapy. By 
employing five TFs, namely FOXO1, ETV2, KLF2, TAL1, and LMO2, which are crucial for 
vessel development, Han et al directly converted mouse adult skin fibroblasts into ECs14. 
Skeletal muscles can also be converted into ECs upon overexpression of er71 in zebrafish15. 
Other approaches employed pluripotency factors, but not vasculogenic/endothelial TFs, to 
initially induce an intermediate state, and then applied angiogenic factors to produce 
progenitor-stage endothelial lineage cells9, 10. These results suggest the feasibility of direct 
reprogramming of non-ECs into ECs, but novel methods for the direct reprogramming need 
to be designed for potential clinical application.
To date, no studies have clearly shown direct reprogramming of human postnatal cells into 
mature ECs with vasculogenic/endothelial TF(s). Since the major use for reprogrammed or 
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induced ECs is for cell therapy or disease investigation, it would be more appropriate to use 
autologous cells as source cells and lineage-specific TFs for reprogramming agents. This 
approach would enable autologous cell therapy and personalized diseased investigation and 
avoid or minimize adverse effects. However, no studies have demonstrated such potential. In 
addition, to reduce the load of external genes in reprogramming, it would be preferable to 
minimize the number of TFs used. This will also facilitate investigation of yet unknown 
mechanisms of direct reprogramming.
Accordingly, we sought to directly reprogram human postnatal cells to ECs with TFs critical 
for EC specification and function. We selected the following seven factors for screening 
through literature search: ETV2, FOXC2, MEF2C, SOX17/SOX18, SMAD1, HEY1/HEY2, 
and NANOG16–24. We used various combinations of these factors and found that ETV2 
alone was best to reprogram fibroblasts into ECs. Previously, we have demonstrated that 
ETV2, a member of the ETS TF family, plays an indispensable role in vessel development as 
evidenced by lack of vasculature in Etv2 deficient mouse embryos21, 25. ETV2 directly binds 
promoters of Flk1, VE-cadherin and Pecam121, 25, 26, and enforced expression of ETV2 in 
mouse ESCs increased expression of these endothelial genes and generation of FLK1+ 
cells21, 27. Here we report that ETV2 transduction to human postnatal fibroblasts can 
generate two stages of rECs which are distinguishable by expression levels of ETV2 and 
more mature EC proteins and duration of culture. We further demonstrate importance of the 
ETV2 transgene-free period followed by reactivation of ETV2 for maturation of rECs. rECs 
were also shown to be effective for repairing limb ischemia when transplanted in vivo.
METHODS
Generation of tetracycline-inducible lentiviral vectors expressing transcription factors and 
production of lentiviral particles
Lentiviral particles of the transcription factors were generated using the FUW-tetO lentiviral 
system, which was re-engineered from FUW-tetO-hOCT4 (Addgene plasmid 20726)28. 
Each transcription factor was cloned into the FUW-tetO lentiviral vector. The resulting 
constructs were co-transfected with pVSVG and pMDL for packaging into 293FT cells 
(Invitrogen) and the supernatant of the 293FT culture was collected at days 2 and 3 post-
transfection, followed by PEG6000-mediated concentration29–31.
Lentiviral transduction
For EC reprogramming, human dermal fibroblasts (HDFs) were incubated with 
constitutively active lentiviral particles expressing the reverse tetracycline transactivator 
FUW-M2rtTA (Addgene plasmid 20342), along with doxycycline (DOX)-inducible 
lentiviral particles containing the EC transcription factors in the presence of polybrene for 
18~24 hours, with virus of MOI 4. After washing, the cells were treated with DOX (2 µg/ml, 
Clontech) containing DMEM supplemented with 10% fetal bovine serum (FBS). The 
medium, replenished with DOX, was changed every other day. After 7 days, the medium 
was replaced with EGM-2 medium (Lonza) containing DOX and the cells were further 
cultured on collagen-coated plates. The medium was changed every 2–3 days for the 
duration of the culture period.
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Induction of hindlimb ischemia and skin wound
All animal experiments were approved by Emory University IACUC. Hindlimb ischemia32 
and skin wound33 were performed on male athymic nude mice as we described previously. 
For the hindlimb ischemia studies, the estimated minimal number for having a meaningful 
difference at 4 weeks is 5, so we included 5 to 10 animals in each group (n = 6 for PBS-, 10 
for HUVEC-, 5 for rEC-injected groups). Before sacrifice for tissue harvest, the mice were 
perfused with fluorescein-labeled Griffonia (Bandeiraea) Simplicifolia Lectin I (BSL1, 
Vector Laboratory Inc.) by direct cardiac injection to stain functional endothelial cells in 
blood vessels. The tissue sections were processed for confocal imaging with a Zeiss LSM 
510 Meta confocal laser scanning microscope and LSM 510 Image software (Carl Zeiss).
Details on the materials and methods, including the following items, can be found in the 
online-only Data Supplement: Flow cytometry32; Acetylated-LDL uptake and UEA1 lectin 
staining32; In vitro tube formation assay32; Immunohistochemistry and 
immunocytochemistry32; Real-time RT-PCR (Table 1 in the online-only Data 
Supplement)32; Microarray; Heat map and clustering analysis34,35; RNA-seq analysis; 
Statistical analysis.
RESULTS
Overexpression of endothelial TFs can convert human postnatal fibroblasts into the EC 
lineage
First, we generated doxycycline (DOX) inducible lentiviral constructs containing the open 
reading frame of each gene (Online Figure I). After transduction into human dermal 
fibroblasts (HDFs), expression of each TF in response to DOX treatment was confirmed by 
quantitative RT-PCR (qRT-PCR) (Online Figure IB). To determine whether these TFs could 
induce expression of EC genes in HDFs, we infected HDFs with a mixture of six of the TFs 
(ETV2, FOXC2, MEF2C, SOX17, SMAD1, HEY1), treated with DOX for 6 or 12 days, and 
conducted qRT-PCR. mRNA expression of EC genes CDH5, KDR, PECAM1, CD34, and 
TEK, but not VWF, were markedly increased compared to the uninfected HDFs (Online 
Figure IC). When NANOG, a direct upstream regulator of KDR in HUVECs18, was 
substituted for SMAD1, no difference was observed (data not shown). Next, we modified the 
protocol: after infecting with the six TFs (with NANOG replacing SMAD1), the cells were 
cultured in DMEM for 7 days and then in endothelial cell culture media until D20 with 
continuous DOX treatment (Figure 1A). From D16, some of the transduced HDFs exhibited 
a cobblestone morphology, a classic feature of ECs (Figure 1B). mRNA expression of 
endothelial genes was gradually increased up to D15, but declined at D20 (Figure 1C). We 
stopped DOX treatment at D20 and cultured these cells up to D39. This change induced 
rebound of endothelial gene expression. In detail, compared to untransduced HDFs at D0, 
mRNA expression of CDH5 at D15 was ~10,000-fold higher, was reduced at D20, but was 
still ~3,500-fold higher at D39. KDR was increased by ~500-fold at D15 and ~1000-fold at 
D39 compared to the control. Expression of TEK, PECAM1 and CD34 showed patterns 
similar to KDR but with less elevated levels at D39: TEK ~5-fold, PECAM1 ~40-fold and 
CD34 ~20-fold. Flow cytometry confirmed expression of endothelial proteins at D39, 
showing that approximately 12–15% of the cells expressed KDR or CDH5 (Figure 1D). A 
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small portion of the cells took up acetylated (Ac)-LDL and formed tube-like structures on 
Matrigel in vitro (Figure 1E). Expression of the six TFs (except HEY1) peaked at D7 and 
declined from D10 (Online Figure II). Taken together, these data indicate that 
overexpression of these six endothelial TFs was able to induce endothelial characteristics in 
human postnatal fibroblasts.
Overexpression of ETV2 alone best induces expression of EC markers in HDFs
In order to determine the minimal essential TFs for EC reprogramming, we first started with 
combinations of 5 factors, omitting one factor from the above six factors. qRT-PCR analyses 
demonstrated that five-factor combinations minus ETV2 showed the most significant 
reduction in major endothelial gene expression such as CDH5 and KDR compared to those 
which included ETV2, suggesting an indispensable role for ETV2 in endothelial 
reprogramming (Figure 2A and 2B). We next designed two series of experiments: one with 
combinations of three or four factors without ETV2 and the other with combinations of 
ETV2 with one or two other factors [ETV2, ETV2+FOXC226, and 
ETV2+FOXC2+NANOG18]. In the former group, no combinations showed higher 
expression of endothelial genes than the ETV2 only group (data not shown). In the latter 
group, we chose those combinations because reports showed potent function of FOXC2 and 
NANOG in endothelial gene expression (Figure 2C)18, 26. Interestingly, only the ETV2 
single factor-treated condition induced the highest expression levels of CDH5, KDR, 
PECAM1, TEK and CD34 (Figure 2C). Inclusion of FOXC2 into ETV2 or ETV2+NANOG 
did not show any synergistic or additive effects on endothelial gene expression compared to 
ETV2 alone. Rather, the expression of endothelial genes decreased upon co-transduction of 
FOCX2 with other factors, suggesting that overexpression of FOXC2 is dispensable for 
direct reprogramming of HDFs into ECs. Collectively, these data strongly argue that ETV2 
alone may be sufficient to convert human postnatal fibroblasts into ECs.
HDFs transduced with ETV2 and cultured short-term show immature EC characteristics 
and have the capability for vessel formation
We then optimized infection conditions of ETV2 and found that multiplicity of infection 
(MOI) 4 induced the highest infection efficiency and the lowest cell death (Online Figure III 
and part of data not shown). HDFs infected with only ETV2 at MOI 4 demonstrated a 
cobblestone appearance as early as D2 (Figure 3A) and expressed CDH5 at ~50% and KDR 
at ~39% by flow cytometric analyses at D7 (Figure 3B). Around ~67% of the KDR+ cells 
also expressed CDH5. During the 7 days culture, 2 × 105 of HDFs used for the infection at 
D0 gave rise to 1.5 × 106 at D7. Thus, it was calculated that one HDF generates 
approximately 3.7 CDH5+ cells, 3 KDR+ cells, and 2 CDH5+KDR+ cells, respectively, upon 
ETV2 transduction. Neither KDR nor CDH5 was expressed in control virus-infected HDFs 
regardless of DOX treatment nor in ETV2-infected HDFs without DOX treatment (Online 
Figure IV). Infection of HDFs with other single factors at MOI 4 did not induce expression 
of EC markers (data not shown). Compared to HDFs at D0, mRNA expression levels of 
endothelial genes were consistently higher in ETV2-transduced HDFs during the first 7 
days, with a peak at day 7 except for CD34 and VWF: CDH5 (~10,000 fold), KDR (~7,000 
fold), TEK (~50 fold), PECAM1 (~50 fold), CD34 (~5 fold), and VWF (~10 fold) (Figure 
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3C). These results showed higher levels of EC gene expression compared to those of the six 
factor-infected HDFs at D15 (Figure 1C).
We then FACS sorted the heterogeneous cells using KDR, a comprehensive marker for 
endothelial-lineage cells, at D7 to enrich endothelial-lineage cells36. The KDR+ cells 
showed substantially higher mRNA expression of endothelial genes compared to the KDR− 
cells (Figure 3C). Compared to HUVECs, KDR+ cells showed similar or higher expression 
of CDH5, KDR and TEK but lower expression of PECAM1 and VWF, which are known 
markers of mature ECs. Western blot analysis (Online Figure V) further confirmed 
expression of all four EC markers, CDH5, KDR, PECAM1, and VWF. Consistent with the 
qRT-PCR results shown in Figure 3C, PECAM1 and VWF levels were weaker in KDR+ 
cells compared to HUVECs. Thus we referred to these cells as early reprogrammed ECs 
(rECs). Expression of S100A4, a fibroblast marker, was significantly reduced in the KDR+ 
cells compared to the KDR− cells or control HDFs suggesting suppression of fibroblast 
nature in the reprogrammed cells (Online Figure VIA). Transduction of HDFs with ETV2 
did not induce expression of pluripotency genes POU5F1 and NANOG (Online Figure VIB 
and VIC). Immunocytochemistry also confirmed that ETV2-infected HDFs at D7 expressed 
CDH5, KDR, VWF and PECAM1 (Figure 3D and Online Figure VII). Approximately 30% 
of these unsorted cells took up Ac-LDL and stained for UEA1 lectin (Online Figure VID–
VIF). KDR+ cells sorted at D7 by magnetic bead-based cell sorting (MACS®) readily 
formed tubular structures, took up Ac-LDL, and stained for UEA1 lectin indicating their 
functional endothelial capability (Figure 3E).
To further evaluate vessel-forming capability in vivo, ETV2-infected HDFs (D7) were 
injected into a mouse skin wound model after being labeled with a red fluorescent dye, CM-
Dil37. Three weeks later, the animals were perfused with BS-1 lectin (BSL1) and the skin 
tissue was prepared for histologic analysis. Confocal microscopic examination of the skin 
demonstrated that the injected cells were either incorporated into vessels and stained for 
BSL1 or localized in close proximity to the vessels, indicating contribution of rECs to vessel 
formation in vivo (Figure 3F). Together, these results show that overexpression of ETV2 was 
able to convert HDFs to functional endothelial cells through direct reprogramming.
Maturation of early rECs to late rECs via booster transduction of ETV2
The low expression of PECAM1 in these early rECs (Figure 3C) indicated a need for further 
reprogramming into a mature EC stage. Thus we attempted a number of protocols by 
varying coating substrates (i.e. collagen, gelatin, Matrigel, OP9 cells), serum percentages, 
culture media, culture duration, and small molecular epigenetic modifiers, and identified 
efficient working conditions. The 7 day-sorted KDR+ cells, i.e. early rECs, were cultured for 
another 20 days in EGM-2 medium supplemented with 15% FBS and 20 ng/ml of VEGF-A 
(Figure 4A). However, the endothelial gene expression was significantly reduced at D30 
(Figure 4B). We therefore treated these cells with DOX, together with valproic acid (VPA) 
for another 6 days to reactivate ETV2, expecting enhanced reprogramming38 (Figure 4A), 
and then further cultivated them in EGM-2 medium supplemented with 5% FBS and 20 
ng/ml of VEGFA until D105 (Online Figure VIIIA). Immediately after reactivation of ETV2 
(D36), the endothelial mRNA expression increased again to the levels of early rECs. After 
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termination of DOX treatment, levels were maintained or increased over the course with 
CDH5 and PECAM1 expression reaching the level of HUVECs at D93 (Figure 4B). 
Immunocytochemistry showed that these cells stained positive for EC markers such as 
CHD5, KDR, PECAM1/CD31 and VWF (Online Figure VII). Flow cytometry analyses 
further confirmed gene expression analyses and immunocytochemistry results, showing a 
gradual increase in both CDH5+ cells and PECAM1+ cells, reaching ~83% and 60% at D93, 
respectively (Figure 4C and 4D). During the long-term culture over 86 days through 12~13 
passages, 2 × 105 of early rECs (KDR+ cells at D7) were culture-expanded to 2 × 109 at 
D93. Thus, it was estimated that one HDF at D0 generated approximately 24,900 CDH5+ 
cells, and 18,000 PECAM1+ cells, respectively, over 93 days. Endothelial morphologies 
were maintained throughout the process (Online Figure VIIIB). They formed tubular 
structures in a Matrigel assay with LDL uptake and binding of UEA1 lectin (Figure 4E). 
Some of these cells also stained positive for 4-amino-5-methylamino-2′,7′-
difluorofluorescein (DAF-FM), a membrane NO-specific fluorescence indicator (Online 
Figure VIIIC), suggesting that these long-term cultured cells are capable of producing nitric 
oxide. qRT-PCR analysis demonstrated that ETV2 expression was 16,000-fold higher in 
early rECs compared to HDFs at D0 (basal level), but in these long-term cultured cells it was 
similar to basal levers (Online Figure IX and Figure 4B). This low expression of ETV2 
together with high expression of mature EC markers, particularly PECAM1, in these long-
term cultured cells suggest their postnatal EC nature and they were referred to as late rECs. 
Our finding is consistent with the previous report7, which showed that suppression of ETV2 
expression is critical for EC maturation during the direct reprogramming process. The 
expression of EC markers was not induced in HDFs transduced with control viral particles 
with or without DOX, or HDFs transduced with lentiviral ETV2 without DOX at D93 
(Online Figure IV). We again evaluated direct vessel-incorporating capability of late rECs in 
vivo. CM-DiI-labeled late rECs were injected into mouse hindlimb ischemia (Figure 4F) and 
skin wound models (Online Figure X) and the animals were perfused with BSL1 and 
sacrificed for histologic analysis at two weeks or three months, respectively. Confocal 
microscopic examination demonstrated that the injected cells were heavily localized around 
vessels and incorporated into vessels as ECs, clearly indicating contribution of late rECs to 
vessel formation in vivo (Figure 4F and Online Figure X). Collectively, these results suggest 
that transient re-induction of ETV2 together with an epigenetic modifier can mature early 
rECs into late rECs, which are also functionally competent for vessel formation.
To further determine to what extent ETV2 re-induction or VPA contributed to the re-
expression of EC genes at day 36, we performed experiments with the following 
combinations: 1) none: no re-induction of ETV2 (no DOX) and no VPA, 2) VPA: VPA 
without re-induction of ETV2 (no DOX), 3) DOX: re-induction of ETV2 (+DOX) without 
VPA, 4) DOX/VPA: re-induction of ETV2 (+DOX) with VPA (Figure 5). These treatments 
were applied between D30 and D36. When analyzing the expression of CDH5, we found 
that only groups having re-induction of ETV2 regardless of VPA treatment (DOX and 
DOX/VPA groups) had significantly increased numbers of CDH5+ cells (Figure 5A and 5B). 
After removing DOX and VPA from D36, both groups maintained the number of CDH5+ 
cells throughout the culture up to D93, with the numbers always being higher in the 
DOX/VPA group compared to the DOX alone group. During this period, the VPA-only 
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treated group showed a slight increase in the number of CDH5+ cells. Overall, a similar 
trend was observed for PECAM1+ cells which showed a more drastic decrease in its 
numbers between D51 and D65 and a later catch-up phenomenon in the DOX and 
DOX/VPA groups (Figure 5C and 5D). The VPA-only treated group showed a marginal 
increase in PECAM1+ cells only at D93. These results suggest that ETV2 is the major factor 
for the reprogramming and that VPA plays an additive role.
Long-term cultured rECs display a transcriptome profile similar to HUVECs
We then compared transcriptome profiles of early (Online Figure XIA and XIC) and late 
rECs (Online Figure XIB and XID) with HDFs and HUVECs. Heat map analyses 
demonstrated that both early- and late rECs showed significantly enriched EC gene 
expression and that the pattern of EC gene expression was closer to HUVECs than to HDFs, 
with late rECs being more similar to HUVECs (Online Figure XIA and XIB). In addition, 
the patterns of fibroblast genes were more analogous between rECs and HUVECs, with late 
rECs sharing a closer signature with HUVECs and significant turnoff of many fibroblastic 
genes (Online Figure XIC and XID). To gain more detailed insight into the transcriptome 
profile during the conversion process, we performed genome-wide RNA sequencing analysis 
on late rECs together with HDFs, human microvascular endothelial cells (HMVECs), and 
HUVECs (Figure 6). We selected 174 EC-related genes (Online Table II) and found that late 
rECs displayed significant induction of EC-related genes, which was more similar to that of 
HMVECs and HUVECs than HDFs (Figure 6A and 6B, p < 2.2e-16). Moreover, Pearson 
correlation analysis of expression of all genes showed that late rECs possess a global 
transcriptional pattern similar to that of HMVECs and HUVECs (Figure 6C, Correlation 
coefficient=0.915 and 0.916, respectively). Through Gene Ontology (GO) analysis with 
9,290 differentially-expressed genes (Online Table III), we found that genes specifically 
expressed in late rECs were related to blood vessel morphogenesis and muscle organ 
development. Compared to HDFs, late rECs were mainly enriched with GO terms associated 
with endothelium development, endothelial cell proliferation and epithelial tube 
morphogenesis (Figure 6D–6F). Comparison of expression profiles (Venn Diagram) of late 
rECs with those of HMVECs and HUVECs showed that 93% of up-regulated genes in late 
rECs were also up-regulated in either HMVECs or HUVECs and 75% of down-regulated 
genes in late rECs were also down-regulated in either HMVECs or HUVECs or (Figure 6E 
and 6F). Together, these gene expression analyses demonstrated that rECs, particularly late 
rECs, closely resemble mature ECs.
Early rEC transplantation enhances recovery from limb ischemia and increases 
neovascularization
Despite immature EC features, early rECs exhibited functional EC characteristics in both in 
vitro and in vivo assays as described above. Thus, we investigated the therapeutic effects of 
early rECs on repair of tissue ischemia. To this end, we intramuscularly injected early rECs 
into nude mice in a hindlimb ischemia model (Figure 7). Laser Doppler perfusion imaging 
revealed significantly enhanced blood perfusion in the early rEC-injected limbs compared to 
the HUVEC-, HDF (transduced with the empty vector + DOX)- or phosphate-buffered saline 
(PBS)-injected limbs at 1, 2, 3, and 4 weeks (Figure 7A and 7B). Mice receiving the early 
rECs showed lower limb loss scores at day 28 compared to the HUVEC-, HDF- or PBS-
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injected mice, indicating better tissue repair (Figure 7C and Online Figure XIIA). The 
capillary density in the hindlimb muscle was significantly higher in the early rEC-injected 
mice than in the HUVEC, HDF-, or PBS-injected mice at day 28 (Figure 7D and Online 
Figure XIIB). Again, confocal microscopic examination demonstrated incorporation of the 
rECs labeled with CM-Dil into the vasculature of the ischemic hindlimbs (Figure 7E). Next, 
to further validate these observations and quantify the incorporated rECs into the vasculature 
of the hindlimbs, we first transduced HDFs with lentiviral ETV2 as well as eGFP (to avoid 
any potential problems with CM-Dil), and sorted KDR+eGFP+ cells at D7 for injection into 
the ischemic hindlimbs. Twenty-eight days after the injection, the tissues were harvested and 
imaged. Three dimensional confocal microscopic analysis revealed that eGFP+ cells were 
clearly co-localized with BSL-Rhodamine-labeled blood vessels (Figure 7F and Online 
Figure XIIIA and XIIIB). Quantitatively, we found that approximately 7% of the injected 
rECs were incorporated into or anastomosed to the blood vessels in the hindlimb tissue 
(Online Figure XIIIC). Concordantly, detailed gene expression analysis revealed that early 
rECs exhibited higher expression levels of representative angiogenic factors such as 
VEGFA, FGF2, ANGPT1, and MMPs compared to HUVECs (Figure 7G). Together these 
data suggest that early rECs can efficiently enhance recovery of hindlimb ischemia and 
promote postnatal neovascularization through both direct vascular incorporation and 
angiogenesis.
DISCUSSION
Recent endothelial reprogramming approaches utilized pluripotency factors, multiple 
vascular TFs, or embryonic cells, which limit their application in cell therapy or disease 
investigation7–10. In our study, several innovations were made in endothelial reprogramming 
strategies. First, this study demonstrated that human postnatal cells can be directly converted 
to ECs, overcoming the major obstacle to using autologous cells for reprogramming. 
Second, we found that ETV2 was able to induce reprogramming of HDFs to ECs. This study 
uncovered a novel role of ETV2 in fate changes of differentiated cells into ECs. Third, we 
also identified two different stages of reprogrammed ECs: early and late rECs. Finally, we 
further demonstrated the therapeutic utility of ETV2-induced rECs in repairing tissue 
ischemia and enhancing neovascularization in vivo.
We found that there were two different stages of reprogrammed ECs. Early rECs, which 
appeared within a week after transduction of ETV2, showed characteristics of immature 
ECs, with mixed signatures of ECs and fibroblasts. The expression of PECAM1 and VWF 
was low while other endothelial genes or proteins were highly expressed. However, early 
rECs were capable of taking up Ac-LDL, formed tubular structures, and contributed to 
vessel formation in animal models, suggesting functional competency as ECs in vitro and in 
vivo. These cells were expandable in culture, enabling their use for cell therapy. Although 
some fibroblast features remained, one could argue that this may be beneficial, as the 
paracrine pro-angiogenic effects of fibroblasts can augment vessel formation39, 40. The early 
rECs were more enriched with angiogenic factors such as VEGFA, FGF2, ANGPT1, and 
MMPs than HUVECs, and after direct injection into ischemic hindlimbs, early rECs 
demonstrated robust reparative effects for tissue ischemia and promoted vessel formation in 
vivo. Regarding the mechanisms underlying therapeutic and vessel-forming effects of early 
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rECs in the hindlimb ischemia model, given the effects of rECs on rapid perfusion recovery 
and vessel formation, the observed effects appear to be attributed more to non-cell 
autonomous effects such as secretion of angiogenic factors than to direct incorporation of 
early rECs into the vessels. With future clinical application in mind, for this study, we 
selected early rECs for testing therapeutic effects on tissue ischemia. The shorter duration of 
culture and fewer transductions of ETV2 required for early rEC generation are advantages 
for clinical use.
Late rECs, which appeared after the second round of ETV2 transduction, showed features of 
more mature stage ECs. We made a number of attempts to increase mature EC genes in early 
rECs. Our initial approach of continuous overexpression of ETV2 did not work, down-
regulating its own expression and most endothelial genes. After a 20-day window without 
transgene overexpression, early rECs responded to 6-day overexpression of ETV2. After this 
booster transduction, no evident dip was noted in the expression of CDH5, KDR, CD34 or 
VWF. We used VPA for enhancing reprogramming as reported for other cell types38. While 
VPA did not affect reprogramming toward early rECs (data not shown), it played an additive 
role for induction to late rECs. Late rECs showed dramatically increased PECAM1 
expression from ~2% to ~60% by flow cytometric analyses, suggesting a transition to a 
more mature endothelial phenotype over long-term culture. The mature nature of late rECs 
was supported by global gene expression analyses that showed repression of fibroblast-
specific genes, more robust expression of mature EC genes, minimal expression of ETV2, 
and production of NO, mimicking the phenotype of HUVECs and HMVECs. Late rECs also 
had the capability to contribute to vessel formation in vivo, and persisted in vessels as ECs at 
least 3 months post-injection, indicating long-term durability in vivo. Due to their mature 
nature, late rECs could be more optimal for the purpose of pathophysiological investigation 
of vascular disease or drug discovery.
Han et al. showed that a combination of five transcription factors (FOXO1, ETV2, KLF2, 
TAL1, and LMO2) was able to directly convert mouse fibroblasts into ECs14. Although the 
four factors without ETV2 resulted in reduced generation of TIE2+ cells as a readout of ECs 
from the fibroblasts, the authors observed that ETV2 was incapable of converting fibroblasts 
into ECs. However, our study demonstrated that ETV2 alone could reprogram human 
fibroblasts into ECs. Similar to our finding, Morita et. al. reported that the single factor 
ETV2 was able to directly convert HDFs to ECs, referred to as ETVECs41. However, there 
are major differences between the two studies. First, the authors claimed that transient 
induction of ETV2 at the initial stage of the process was sufficient for the conversion into 
and the maintenance of ETVECs. However, this study demonstrated continued 
overexpression of ETV2 in their ETVECs. ETVECs are PECAM1high cells selectively 
sorted at 15 days after ETV2 overexpression and expressed ETV2 at very high levels during 
the culture period of more than 50 days. It is well known that ETV2 is not or minimally 
expressed in any mammalian postnatal ECs42–44. Indeed, sustained expression of ETV2 in 
vascular endothelial cells during embryogenesis leads to vascular abnormality as evidenced 
by dilated vessels in the extraembryonic yolk sac45, suggesting that a transient expression of 
ETV2 is critical for ensuring proper development of the vascular system. In agreement with 
this report, a study showed an inverse relationship between the expression of ETV2 and 
PECAM1 during the direct conversion of non-ECs to ECs7. Further, they found that short-
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term, but not continued, expression of ETV2 in the early phase of the reprogramming 
process is critical for the generation of induced ECs with a mature phenotype. Thus, we 
argue that ETVECs are not reprogrammed or induced ECs but rather selected cells that show 
the ectopic expression of EC markers and some characteristics of ECs due to overexpression 
of ETV2. Since key EC genes including CDH5 and PECAM1 are direct targets of 
ETV246, 47, extreme overexpression of ETV2 leads to forced expression of such EC genes in 
selected cell colonies, as shown in their study. This also explains why ETVECs highly 
express PECAM1, a direct downstream target of ETV2, from the beginning and throughout, 
and why no maturation process was shown or observed in the study throughout the duration 
of culture. In contrast, our study found that PECAM1, which represents a more mature 
marker, showed low expression at an early stage of reprogramming when ETV2 was highly 
expressed but PECAM1 expression at both the mRNA and protein levels was progressively 
and concordantly increased over maturation (Figure 5). Most importantly, our late rECs, had 
minimal expression of transduced ETV2, which is an obligatory characteristic of genuine 
postnatal human ECs. Moreover, late rECs, but not ETVECs, produced nitric oxide, which 
provides additional evidence of mature ECs. Second, our study demonstrated that there is 
discontinuity in the reprogramming process toward rECs and continuous expression of 
ETV2 cannot sustain a phenotype of rECs and mature rECs. Only after an ETV2-free period 
followed by temporary re-induction of ETV2 could the phenotype of early rECs be 
surpassed, entering into the maturation process. Third, Morita’s study reported an important 
role for FOXC2 in the induction of reprogramming by ETV2. However, we found that 
overexpression of FOXC2 was dispensable in EC reprogramming. Fourth, there is much 
critical information missing in their study41. For example, there is no information regarding 
the reprogramming efficiency or the role of ETVECs in in vivo studies. Also, the vascular 
incorporation capability is unconvincing.
Elucidating mechanisms of direct endothelial conversion is crucial for understanding the 
reprogramming process and enhancing the efficiency of generating reprogrammed ECs. It 
remains to be determined how ETV2 activates EC genes while suppressing fibroblast genes 
during the reprogramming process. Although ETV2 is a potent vasculogenic TF 
upregulating endothelial genes in development21, 26, 48, 49, as yet no studies have 
demonstrated the mechanisms by which ETV2 directly reprograms somatic cells to ECs. We 
have previously shown that ETV2 can induce de novo formation of KDR+ cells through 
direct binding to the promoter of the gene21. These results have been supported by other 
studies26, 50–52. In a subsequent study, using a genome wide ChIP-sequencing approach, we 
have clearly demonstrated a significant induction of genes critical for endothelial cell 
generation and function by ETV246. Together with our results showing rapid and significant 
induction of endothelial genes upon ETV2 transduction into HDFs, it is likely that the 
reprogramming process can also be achieved in part by direct action of ETV2 on vasculo-
angiogenic genes. Moreover, since overexpression of ETV2 in fibroblasts induced global 
changes in gene expression, ETV2 might have directly modulated epigenetic targets. In fact, 
ETV2 was shown to interact with Jmjd1a53, 54, a histone demethylase. Thus, it is tempting to 
speculate that overexpressed ETV2 in HDFs not only activates endothelial genes directly, 
but also induces epigenetic changes, probably through interactions with histone and/or DNA 
modifying molecules. As intriguing are the mechanisms underlying maturation or transition 
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of early rECs to late rECs, because in adult endothelial cells, ETV2 is not, or is very 
minimally, expressed42–44, 55. Moreover, it remains to be determined why VPA has additive 
effects in promoting reprogramming into late rECs. Further studies are necessary to address 
the mechanisms of ETV2-mediated EC reprogramming.
Taken together, the successful demonstration of direct reprogramming of human postnatal 
somatic cells into ECs via a single TF, ETV2, in this study will facilitate the understanding 
of direct reprogramming of fibroblasts to ECs and its utilization in biomedical science. 
Specifically, this novel reprogramming approach and the resultant two stages of rECs will 
enable autologous cell therapy, individualized drug testing, and personalized disease 
investigation for various cardiovascular diseases. The next step would be to employ non-
integrating episomal vectors or substitute a non-genetic method for lentiviral vectors, as 
were recently developed for iPSC generation56–60.
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NOVELTY AND SIGNIFICANCE
What is Known?
• Vascular Endothelial cells (ECs) plays key roles in vessel formation and 
ischemic tissue repair.
• ETV2 is an indispensable transcription factor for endothelial lineage 
specification during development.
• Direct lineage conversion or reprogramming is an emerging technology to 
generate target cells via overexpression of cell-type-specific transcription 
factors, bypassing the pluripotent stem cell stage.
What New Information Does This Article Contribute?
• ETV2 alone is sufficient to induce direct conversion of human dermal 
fibroblasts into ECs, referred to as reprogrammed ECs (rECs).
• Implantation of rECs promote neovascularization and ischemic tissue repair.
• We found at least two different stages of rECs, early and late rECs, which 
respectively demonstrate immature and mature EC characteristics.
Direct reprogramming with cell-type-specific TFs emerged as a promising strategy to 
generate target cells. Although studies demonstrated the feasibility of direct conversion of 
non-ECs into ECs, no studies have shown direct reprogramming of human postnatal cells 
into mature ECs with endothelial TFs. Among various combinations of seven EC TFs, we 
found ETV2 alone was sufficient to reprogram human fibroblasts into ECs. We further 
found that direct reprogramming by ETV2 generated at least two distinct stages of rECs: 
early and late rECs. Early rECs exhibited characteristics of immature ECs, but had 
functional and therapeutic potential for repairing ischemic disease and promoting vessel 
formation. Late rECs, which appeared after further cultivation of early rECs with a 
second round of ETV2 transduction showed features of more mature ECs and the ability 
to contribute to vessel formation. These new types of ECs generated by direct 
reprogramming provide novel opportunities for autologous cell therapy for cardiovascular 
diseases, drug discovery, disease modeling, and precision medicine. Moreover, this 
reprogramming protocol as well as the two types of rECs can allow investigation of yet 
unknown mechanisms of direct endothelial reprogramming from fully differentiated 
somatic cells.
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Figure 1. Reprogramming of HDFs to ECs with six EC transcription factors
(A) A schematic of the reprogramming protocol. (B–E) Endothelial characteristics of HDFs 
infected with lentiviral particles of six TFs (ETV2, FOXC2, MEF2C, SOX17, NANOG, 
HEY1). The infected HDFs exhibited cobblestone appearance (B), expressed endothelial 
genes and proteins measured by qRT-PCR (C) and flow cytometry (D), and were able to take 
up Ac-LDL (red) and form tubular structures (E). Scale bars: (B) 400 µm, (E) 200 µm 
(yellow) and 1 mm (black). All data are presented as mean ± s.e.m.; three independent 
experiments, each with technical triplicates.
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Figure 2. ETV2 is essential for reprogramming of HDFs to endothelial cells
(A and B) qRT-PCR results of HDFs infected with combinations of five TFs for CDH5 (A) 
and KDR (B) at day (D) 6, 12, and 18. (C) qRT-PCR results of HDFs infected with one to 
three TFs including ETV2 for various EC genes at D0, 4, and 7. All data are presented as 
mean ± s.e.m.; three independent experiments, each with technical triplicates.
Lee et al. Page 20
Circ Res. Author manuscript; available in PMC 2018 March 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lee et al. Page 21
Circ Res. Author manuscript; available in PMC 2018 March 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lee et al. Page 22
Circ Res. Author manuscript; available in PMC 2018 March 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Endothelial characteristics of the single factor ETV2-transduced, short-term cultured 
HDFs
(A) Morphologic changes showing emergence of cobblestone appearance in HDFs as early 
as D2 after transduction with ETV2. (B) Flow cytometric analyses of transduced HDFs at 
D7 showing expression of CDH5 and KDR. It also shows that about 67% of KDR+ cells 
expressed CDH5. All data are presented as mean ± s.e.m.; three independent experiments, 
each with technical triplicates. ***P < 0.001 vs. isotype control, standard unpaired student t 
test. (C) qRT-PCR analyses demonstrated induction of various endothelial genes in ETV2-
transduced HDFs. At D7, the results of unsorted cells and the sorted KDR+ and KDR− cells 
are shown. KDR+ cells showed significantly higher endothelial gene expression (except 
VWF) compared to unsorted (D7) and KDR− cells. All data are presented as mean ± s.e.m.; 
three independent experiments, each with technical triplicates. ***P < 0.001, **P < 0.01, *P 
< 0.05, standard unpaired Student’s t test. (D) Immunohistochemistry showed expression of 
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CDH5 and KDR (upper panel), and VWF and PECAM1 (lower panel) in transduced HDFs 
at D7. (E) The sorted KDR+ cells at D7 formed tubes on Matrigel, also showing Ac-LDL 
uptake (red) and UEA1 lectin (green) binding. (F) Contribution of reprogrammed HDFs to 
vessel formation. The transduced HDFs at D7 were labeled with CM-Dil (red), and injected 
into the wounded skin of mice. Three weeks later, the mice were perfused with BS1 lectin 
(FITC-BSL1), and tissues were processed for confocal microscopic imaging. Injected cells 
(red) were either incorporated into the blood vessels as shown by colocalization with BSL1 
(green) (arrows) or localized in close proximity to the vessels, indicating contribution to 
vessel formation. DAPI (blue). Scale bars: (A, E) 400 µm, (D) 100 µm, (G) 25 µm.
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Figure 4. Endothelial characterization of long-term cultured KDR+ cells isolated from ETV2-
tranduced HDFs, late rECs
(A) A schematic of the culture protocol for long-term cultured ETV2-transduced HDFs, late 
rECs. (B–D) Endothelial characteristics of the long-term cultured KDR+ cells in vitro which 
were FACS-sorted from ETV2-tranduced HDFs at D7. qRT-PCR analysis (Y axis shown in 
log scale) (B) and flow cytometric analysis (C, D) demonstrated increased expression and 
maintenance of EC genes and proteins to D93. The green lines or arrows indicate the time 
point of reinduction of ETV2 expression via DOX. Note that ~60% of the cells are positive 
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for PECAM1 at D93 (D). All data are presented as mean ± s.e.m.; three independent 
experiments, technical triplicates/experiment for qRT-PCR analysis, single/experiment for 
flow cytometric analysis. ***P < 0.001, **P < 0.01, *P < 0.05, vs. D0;###P < 0.001,##P < 
0.01,#P < 0.05, vs. D7, standard unpaired Student’s t test. The cells at D93 were able to form 
tubular structures and stained positive for Ac-LDL and UEA1-lectin (E). (F) Cells prepared 
at D93 were labeled with CM-Dil and injected into mice in a hindlimb ischemia model. The 
mice were perfused with FITC-BSL1 at 3 months, and subjected to immunohistochemistry 
for confocal microscope imaging. Injected cells (red) were either incorporated into the blood 
vessels and expressed BSL1 (green) (arrows) or localized close to the vessels, indicating 
contribution to vessel formation. DAPI (blue). Scale bars: (E) 200 µm, (F) 25 µm.
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Figure 5. Flow cytometric analysis of rECs after re-induction of ETV2 by DOX and treatment 
with VPA
Flow cytometric analyses of CDH5 (A and B) and PECAM1 (C and D) in rECs after the 
following treatments. None (blue): no re-induction of ETV2 (no DOX) and no VPA, VPA 
(red): VPA without re-induction of ETV2 (no DOX), DOX (green): re-induction of ETV2 
(+DOX) without VPA, DOX/VPA (purple): re-induction of ETV2 (+DOX) with VPA. 
Shown are the representative plots of flow cytometry (A and C) and their quantification 
results (B and D). All data are presented as mean ± s.e.m.; three independent experiments.
Lee et al. Page 29
Circ Res. Author manuscript; available in PMC 2018 March 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. Transcriptome analysis on late rECs via RNA sequencing
(A) Heatmap representing EC-related genes with 2-fold difference. Expression values 
relative to the average expression values across all samples were represented by colors from 
green to red (log2 scale). (B) Comparison of EC-related genes among four samples. *P < 
0.05 by two-sided Student’s t test. (C) Global gene expression similarity among HDFs, 
rECs, HMVECs and HUVECs. The color from black to yellow represents Pearson 
correlation. (D) Heatmap showing differentially-expressed genes in rECs, HMVECs and 
HUVECs compared to HDFs. Relative expression levels to median value with log2 scale 
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were shown by green to red colors. Representative GO terms and gene symbols were also 
shown in right panel. (E) Overlap of highly-expressed genes (> 2 fold) among rECs, 
HMVECs and HUVECs. The right panel represents significant GO terms of up-regulated 
genes. (F) Overlap of lowly-expressed genes (> 2 fold) among rECs, HMVECs and 
HUVECs. The right panel represents significant GO terms of down-regulated genes.
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Figure 7. Enhanced blood flow recovery and neovascularization by rECs in ischemic hindlimbs
Early rECs were intramuscularly injected into ischemic himdlimbs of nude mice. (A, B) 
Laser Doppler perfusion images (A) and quantitative analysis of blood flow (B) showed 
improved limb perfusion in the rEC- compared to the HUVEC-, HDF- or PBS-group. All 
data are presented as mean ± s.e.m.; n = 5 for rEC-, 10 for HUVEC-, 5 for HDF-, or 6 for 
PBS-group. ***P < 0.001, **P < 0.01, Repeated Measures ANOVA followed by multiple 
comparisons with Bonferroni’s method. (C) The rEC-injected group showed lower limb loss 
score compared to the HUVEC-, HDF-, or PBS-groups at day 28, suggesting better limb 
protection. All data are presented mean ± s.e.m.; n = 5 for rEC-, 10 for HUVEC-, 5 for 
HDF-, or 6 for PBS-group. **P < 0.01, *P < 0.05, standard unpaired Student’s t test. (D) 
The mice were perfused with FITC-BSL1 at 4 weeks and the frozen-sections of the muscle 
were examined under confocal microscope imaging. Quantitative analysis of vascular 
density is shown. Note that the vascular density was significantly increased in the rEC-, 
compared to the HDF-, HUVEC- or PBS-groups. All data are presented as mean ± s.e.m.; n 
= 5 for rEC-, 10 for HUVEC-, 5 for HDF-, or 6 for PBS-group. ***P < 0.001, **P < 0.01, 
standard unpaired Student’s t test. (E) Injected rECs (red) were incorporated into the blood 
vessels (green) as indicated by arrows, suggesting contribution of the rECs to vessel 
formation. DAPI (blue). Scale bars: 25 µm. (F) Early rECs transduced with lentiviral-eGFP 
(green) were injected into ischemic hindlimbs. The mice were perfused with Rhodamine-
BSL1 (red) at 28 days and the frozen-sections of the hindlimb muscle were subjected to 
confocal microscope imaging. The co-localization of GFP-rEC (green) and BSL1-labeled 
blood vessel (red) is indicated by arrows and confirmed by orthogonal image. Scale bars: 50 
µm. (G) Increased expression levels of angiogenic genes in early rECs compared to 
HUVECs. Red and green indicate decreased and increased levels of gene expression, 
respectively.
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